Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Sponsor: Bausch & Lomb Incorporated
Summary
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
Official title: A Phase 2 Evaluation of the Safety, Ocular Tolerability, and Efficacy of Topical Ophthalmic BL1107 Versus Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
228
Start Date
2025-10-24
Completion Date
2026-05
Last Updated
2026-03-31
Healthy Volunteers
No
Conditions
Interventions
BL1107 Low dose
Dosed twice daily for 28 days.
BL1107 High dose
Dosed twice daily for 28 days.
Timolol maleate 0.5%
Dosed twice daily for 28 days.
Locations (14)
Global Research Management, Inc.
Glendale, California, United States
Eye Research Foundation
Newport Beach, California, United States
California Eye Specialist Medical Group, LLC
Pasadena, California, United States
Eye Associates of Fort Myers
Fort Myers, Florida, United States
Levenson Eye Associates
Jacksonville, Florida, United States
Central Florida Eye Associates
Lakeland, Florida, United States
Lee Shettle Eye and Hearing
Largo, Florida, United States
Clayton Eye Clinical Research, LLC
Morrow, Georgia, United States
Coastal Research Associates, LLC
Roswell, Georgia, United States
Heart of America Eye Care
Shawnee Mission, Kansas, United States
Andover Eye Associates
Andover, Massachusetts, United States
Scott & Christie and Associates, PC
Cranberry Township, Pennsylvania, United States
Total Eye Care, P.A.
Memphis, Tennessee, United States
Houston Eye Associates
Houston, Texas, United States